Trial Profile
Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2019
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ataxia telangiectasia
- Focus Adverse reactions; Registrational
- Acronyms OLE-IEDAT
- Sponsors EryDel
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2018 New trial record